Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma

References

• Smith M R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359–7368
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp M J, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071
   PubMed Web of Science ®Google Scholar
• Bergsagel P L, Smith A M, Szczepek A, Mant M J, Belch A R, Pilarski L M. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19 + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 1995; 85: 436–447
   PubMed Web of Science ®Google Scholar
• Pilarski L M, Giannakopoulos N V, Szczepek A J, Masellis A M, Mant M J, Belch A R. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res 2000; 6: 585–596
   PubMed Web of Science ®Google Scholar
• Rasmussen T. The presence of circulating clonal CD19 + cells in multiple myeloma. Leuk Lymphoma 2001; 42: 1359–1366
   PubMed Web of Science ®Google Scholar
• Matsui W, Huff C A, Wang Q, Malehorn M T, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332–2336
   PubMed Web of Science ®Google Scholar
• Szczepek A J, Seeberger K, Wizniak J, Mant M J, Belch A R, Pilarski L M. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood 1998; 92: 2844–2855
   PubMed Web of Science ®Google Scholar
• Zojer N, Schuster-Kolbe J, Assmann I, Ackermann J, Strasser K, Hübl W, et al. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19 + cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol 2002; 117: 852–859
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Treon S P, Pilarski L M, Belch A R, Kelliher A, Preffer F I, Shima Y, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25: 72–81
   PubMed Web of Science ®Google Scholar
• Musto P, Carella A M, Jr, Greco M M, Falcone A, Sanpaolo G, Bodenizza C, et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol 2003; 123: 746–747
   PubMed Web of Science ®Google Scholar
• Gemmel C, Cremer F W, Weis M, Witzens M, Moldenhauer G, Koniczek K H, et al. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 2002; 81: 119–123
   PubMed Web of Science ®Google Scholar
• Treon S P, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24: 263–271
   PubMed Web of Science ®Google Scholar
• Korte W, Jost C, Cogliatti S, Hess U, Cerny T. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Ann Oncol 1999; 10: 1249–1250
   PubMed Web of Science ®Google Scholar
• Hofer S, Hunziker S, Dirnhofer S, Ludwig C. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. Br J Haematol 2003; 122: 690–691
   PubMed Web of Science ®Google Scholar
• Wiestner A, Cho H J, Asch A S, Michelis M A, Zeller J A, Peerschke E I, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426–3428
   PubMed Web of Science ®Google Scholar
• Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101: 3857–3861
   PubMed Web of Science ®Google Scholar
• Edwards J C, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D R, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 2004; 350: 2572–2581
   PubMed Web of Science ®Google Scholar
• Gottenberg J E, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64: 913–920, for Club Rheumatismes et Inflammation (CRI)
   PubMed Web of Science ®Google Scholar
• Lim S H, Zhang Y, Wang Z, Varadarajan R, Periman P, Esler W V. Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood 2004; 103: 1971–1972
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Fonseca R, Greipp P R, Blood E, Rue M, Vesole D H, et al. Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004; 101: 2593–2598
   PubMed Web of Science ®Google Scholar
• Treon S P, Branagan A R, Hunter Z, Santos D, Tournhilac O, Anderson K C. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004; 15: 1481–1483
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Johnsen H E, Lodahl M, Kuehl M. In multiple myeloma 14q32 translocations are present in memory B cells but ras mutations are restricted to the plasma cell compartment. Xth International Myeloma Workshop, Sydney 2005
   Google Scholar